Many market players felt the company was guilty by (apparent) association with legacy technology.

Salesforce trails its tech large-cap peers and is the second-worst performer in the Dow this year, ahead of only UnitedHealth. The company's growth rate has been below 10% since mid-2024, and analysts ...

I'm downgrading Salesforce to a sell rating with the stock approaching an ~8x revenue multiple, with category leadership in tech likely to shift to small/mid-caps. Revenue in the company's ...